Avoiding the Adverse Effects of Causality Assessments

Unfortunately, adverse drug reaction reports collected and causality assessments made in the course of post-marketing surveillance have increasingly become fodder for plaintiffs' attorneys attempting to prove causation. Courts, however, properly have precluded plaintiffs from presenting post-marketing surveillance materials, most recently refusing to allow plaintiffs to introduce company causality assessments based on adverse drug reaction reports as evidence of causation and from using these reports and assessments as bases for expert opinions on causation.

32 minute readFebruary 28, 2008 at 07:03 AM
By
Andrea E.K. Thomas
Joseph K. Scully
Avoiding the Adverse Effects of Causality Assessments

In the present climate of constant news reports of product recalls and runaway verdicts, pharmaceutical manufacturers are concerned about certain information that can infiltrate and unfairly influence product liability trials.

This premium content is locked for LawJournalNewsletters subscribers only

ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts
Subscribe Now

Already have an account? Sign In Now

For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.

NOT FOR REPRINT

© 2026 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Continue Reading

Analyzing the CCPA’s New Risk Assessment Requirement

Businesses subject to the CCPA now must conduct risk assessments for certain types of processing activities and, starting in 2028, must certify to California regulators that they completed the assessments.

February 01, 2026

Accountability and Precision Will Define the Next Phase of AI Adoption

The firms that will thrive when it comes to the adoption of AI will not be those with the most tools or the most prompts. They will be the ones with clear standards, defined human ownership and a dedicated AI partner able to turn raw generation into reliable, high‑value content.

February 01, 2026

AI Requires Law Firms to Rethink Business Models

Artificial intelligence is changing how legal work is performed. What’s needed is problem-solving optimism, a clinical appraisal of the firm’s capabilities and economic position, and earnest resolve to change before market pressure forces change under duress.

February 01, 2026

Using Private AI Tools Can Improve Ethical Compliance

The ethical use of AI should be a prerequisite for the integration of AI into a legal practice. Failure to learn and implement transparency, accountability, and best practices for responsible AI usage prior to employing AI will likely result in ethical and malpractice difficulties.

February 01, 2026